Traded Jul 30 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Traded Jul 2, 2026 · Filed Jul 3, 2026
The CEO of United Therapeutics sold $71K of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$71,338
Shares × reported transaction price
57 days after results of May 6, 2026, 34 days before results of Aug 5, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −2.1% | −0.3% | −1.9% |
| 30 days | −5.2% | +2.5% | −7.6% |
| 90 days | −2.0% | +3.1% | −5.1% |
Past results only. Not a forecast.
Traded Jul 30 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Martine A Rothblatt (Chairperson & CEO) sold ~$337K of United Therapeutics
Scheduled in advanceMartine A Rothblatt (Chairperson & CEO) sold ~$778K of United Therapeutics
Scheduled in advance